PMID- 21732783
OWN - NLM
STAT- MEDLINE
DCOM- 20110914
LR  - 20210527
IS  - 1543-2165 (Electronic)
IS  - 0003-9985 (Linking)
VI  - 135
IP  - 7
DP  - 2011 Jul
TI  - Application of thrombolytic drugs on clotted blood and bone marrow specimens to 
      generate usable cells for cytogenetic analyses.
PG  - 915-9
AB  - CONTEXT: Clotted blood and bone marrow specimens account for a large proportion 
      of failed cytogenetic studies. There are no published protocols describing 
      salvage of clotted specimens such that conventional chromosome or fluorescence in 
      situ hybridization (FISH) studies can be performed. OBJECTIVE: To evaluate the 
      utility of thrombolytic drugs on clotted blood samples to yield intact cells 
      suitable for cytogenetic analysis. DESIGN: Five commercially available 
      thrombolytic drugs (alteplase, urokinase, streptokinase, tenecteplase, reteplase) 
      were evaluated in a series of blinded experiments to identify the best drug for 
      lysing clots to produce samples suitable for chromosome and FISH studies. After 
      the selection of alteplase as the drug yielding the most promising results, a 
      comparative study between alteplase (0.75 mg/ml) and a commercially available 
      anticlotting reagent (ACR) was performed. For each sample, mitotic index, 
      chromosome length, and quality of slides prepared for conventional chromosome and 
      FISH analyses were evaluated. RESULTS: Alteplase-treated samples produced a 
      higher mitotic index than those treated with ACR while showing equivalent quality 
      in conventional chromosome and FISH studies. We have demonstrated the utility of 
      treating clotted blood samples with alteplase before cell culture to yield cells 
      suitable for cytogenetic analysis. Since clinical implementation, this technique 
      has been applied to more than 250 bone marrow samples, with a 93% success rate. 
      CONCLUSIONS: We believe the routine use of alteplase on clotted blood and bone 
      marrow specimens should become standard for cytogenetics laboratories and may 
      have similar utility in salvaging clotted specimens for other clinical assays 
      requiring intact cells for analysis.
FAU - St Antoine, Angelique
AU  - St Antoine A
AD  - Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, 
      Mayo Clinic, Rochester, Minnesota 55905, USA.
FAU - Ketterling, Morgan N
AU  - Ketterling MN
FAU - Sukov, William R
AU  - Sukov WR
FAU - Lowman, Josh
AU  - Lowman J
FAU - Knudson, Ryan A
AU  - Knudson RA
FAU - Sinnwell, Jason P
AU  - Sinnwell JP
FAU - Wiktor, Anne E
AU  - Wiktor AE
FAU - Ketterling, Rhett P
AU  - Ketterling RP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - 0 (Fibrinolytic Agents)
SB  - IM
MH  - Blood Coagulation
MH  - Cytogenetic Analysis/*methods
MH  - *Fibrinolytic Agents
MH  - Humans
EDAT- 2011/07/08 06:00
MHDA- 2011/09/15 06:00
CRDT- 2011/07/08 06:00
PHST- 2011/07/08 06:00 [entrez]
PHST- 2011/07/08 06:00 [pubmed]
PHST- 2011/09/15 06:00 [medline]
AID - 10.1043/2010-0085-OAR1.1 [pii]
AID - 10.5858/2010-0085-OAR1.1 [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2011 Jul;135(7):915-9. doi: 10.5858/2010-0085-OAR1.1.